Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cross Frequency tACS on Cognitive Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 35 years~* Able to provide informed consent~* Willing to comply with all study procedures and be available for the duration of the study Speak and understand English~Exclusion Criteria:~* Attention Deficit Hyperactivity Disorder (currently under treatment)~* Neurological disorders and conditions, including, but not limited to:~* History of epilepsy~* Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia~* History of stroke~* Parkinson's disease~* Multiple sclerosis~* Cerebral aneurysm~* Brain tumors~* Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy)~* Prior brain surgery~* Any brain devices/implants, including cochlear implants and aneurysm clips~* History or current traumatic brain injury~* (For females) Pregnancy or breast feeding~* Personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.)~* Positive urine test for the following: Marijuana (THC), Cocaine (COC), Phencyclidine (PCP), Amphetamine (AMP), Ecstasy (MDMA), Methamphetamine (Mamp), Opiates (OPI), Oxycodone (OXY), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Tricyclic Antidepressants (TCA), Propoxyphene (PPX)~* Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Theta-gamma, Delta-beta, Sham (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS
- Theta-gamma, Sham, Delta-beta (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS
- Delta-beta, Theta-gamma, Sham tACS (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS
- Delta-beta, Sham, Theta-gamma tACS (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS
- Sham, Delta-beta, Theta-gamma tACS (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS
- Sham, Theta-gamma, Delta-beta tACS (Type: EXPERIMENTAL): Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS

Based on this trial design, predict the completion outcome and termination type (if applicable).